Date: 2012-10-02
Type of information: Grant
Company: Vaximm (Switzerland - Germany)
Investors: Federal Ministry of Education and Research (BMBF) (Germany)
Amount:
Funding type: grant
Planned used: Vaximm’s lead candidate VXM01 is an oral T-cell vaccine, which targets the tumor vasculature. It is currently in Phase I/II clinical evaluation in pancreatic cancer patients at the Heidelberg University Hospital. The funding from the leading-edge cluster program will be used to develop additional cancer vaccines complementary to VXM01, which are based on the same oral T-cell vaccine technology. A second candidate (VXM06), which targets an undisclosed, abundant, tumor-specific antigen, is already in preclinical development. Two further product candidates are at discovery stage.
Others: Vaximm, a Swiss-German biotech company focusing on cancer vaccines, has announced that its German subsidiary VAXIMM GmbH has been awarded a grant from theBioRN cluster “Cell-based and Molecular Medicine” to expand its oral T-cell vaccine technology platform. The cluster competition is a program of Germany´s Federal Ministry of Education and Research (BMBF) to promote top-notch innovation in Germany.
Therapeutic area: Cancer - Oncology
